Vaccines · 2020 · 24 citations · 36 references
Life SciencesBiotechnologyImmunologyImmunizationVaccinologyVirologyAntibody-antigen RecognitionAntiviral ImmunityHiv Vaccine DevelopmentVaccine PlatformsViral VaccinesVirus-like Particle VaccinesAntibodiesHeterologous Prime-boost VaccinationMultivalent VaccinesPrime-boost Immunization RegimensRecombinant Virus-like ParticlesVirus-like Particle ImmunogenicityVirus-like Particle Vaccine PlatformsVirus-like Particles
Broadly neutralizing antibodies (bnAbs) isolated from HIV-infected individuals delineate vulnerable sites on the HIV envelope glycoprotein that are potential vaccine targets. A linear epitope within the N-terminal region of the HIV-1 fusion peptide (FP8) is the primary target of VRC34.01, a bnAb that neutralizes ~50% of primary HIV isolates. FP8 has attracted attention as a potential HIV vaccine target because it is a simple linear epitope. Here, platform technologies based on RNA bacteriophage virus-like particles (VLPs) were used to develop multivalent vaccines targeting the FP8 epitope. Both recombinant MS2 VLPs displaying the FP8 peptide and Qβ VLPs displaying chemically conjugated FP8 peptide induced high titers of FP8-specific antibodies in mice. Moreover, a heterologous prime-boost-boost regimen employing the two FP8-VLP vaccines and native envelope trimer was the most effective approach for eliciting HIV-1 neutralizing antibodies. Given the potent immunogenicity of VLP-based vaccines, this vaccination strategy-inspired by bnAb-guided epitope mapping, VLP bioengineering, and prime-boost immunization approaches-may be a useful strategy for eliciting bnAb responses against HIV.
36
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Hua‐Xin Liao, Rebecca M. Lynch, Tongqing Zhou et al. · Nature · 2013 · 1.1K citations · Full text
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jinghe Huang, Gilad Ofek, Leo Laub et al. · Nature · 2012 · 847 citations · Full text
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Nicole A. Doria‐Rose, Chaim A. Schramm, Jason Gorman et al. · Nature · 2014 · 752 citations · Full text
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
Rui Kong, Kai Xu, Tongqing Zhou et al. · Science · 2016 · 377 citations · Full text